DOTA Zoledronate
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].
Product Specifications
CAS Number
1908409-18-6
UNSPSC
12352005
Target
Radionuclide-Drug Conjugates (RDCs)
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-zoledronate.html
Solubility
10 mM in DMSO
Smiles
O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(NCCC2=CN(CC(P(O)(O)=O)(O)P(O)(O)=O)C=N2)=O)CC(O)=O)O
Molecular Formula
C23H41N7O14P2
Molecular Weight
701.56
References & Citations
[1]The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb2909087-01 20 µg
Recombinant Uncharacterized protein Mb1321c (Mb1321c)
Sign In for Pricing
View Details orb2909087-02 100 µg
Recombinant Uncharacterized protein Mb1321c (Mb1321c)
Sign In for Pricing
View Details